Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.88% | 63.18 | 1.0% | $430.38m | |
| AMGN | Amgen, Inc. | -0.19% | 237.16 | 1.3% | $414.62m | |
| BIIB | Biogen, Inc. | 0.47% | 288.54 | 1.4% | $364.69m | |
| ILMN | Illumina, Inc. | 0.91% | 331.32 | 3.5% | $326.51m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.66% | 235.54 | 1.9% | $275.17m | |
| EXAS | EXACT Sciences Corp. | 9.00% | 93.63 | 24.0% | $214.85m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.36% | 358.78 | 2.6% | $214.32m | |
| ITCI | Intra-Cellular Therapies, Inc. | -0.71% | 25.25 | 9.0% | $172.23m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.50% | 111.31 | 2.0% | $170.45m | |
| INCY | Incyte Corp. | 0.39% | 78.96 | 2.5% | $135.65m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.68% | 120.93 | 14.6% | $130.81m | |
| A | Agilent Technologies, Inc. | 0.67% | 90.21 | 1.6% | $120.85m | |
| BMRN | BioMarin Pharmaceutical, Inc. | 0.57% | 88.05 | 4.3% | $106.77m | |
| BLUE | bluebird bio, Inc. | -2.47% | 93.45 | 14.2% | $92.91m | |
| SGEN | Seattle Genetics, Inc. | 1.79% | 110.62 | 6.1% | $91.95m |
Company Profile
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.